MicroRNAs (miR)-221 and miR-222, both overexpressed in human thyroid papillary carcinomas, regulate p27Kip1 protein levels and cell cycle

Endocrine-Related Cancer

Volumn 14, Issue 3, 2007, Pages 791-798

  Visone, Rosa ^a,b,c   Russo, Lucia ^c   Pallante, Pierlorenzo ^a,c   De Martino, Ivana ^a,c   Ferraro, Angelo ^c   Leone, Vincenza ^c   Borbone, Eleonora ^c   Petrocca, Fabio ^b   Alder, Hansjuerg ^b   Croce, Carlo Maria ^b   Fusco, Alfredo ^a,c  

^a UNIVERSITY OF NAPLES FEDERICO II   (Italy)

^b OHIO STATE UNIVERSITY   (United States)

^c CEINGE BIOTECNOLOGIE AVANZATE   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLIN DEPENDENT KINASE INHIBITOR 1B; MESSENGER RNA; MICRORNA;

3' UNTRANSLATED REGION; ARTICLE; CELL CYCLE; CELL CYCLE S PHASE; CONTROLLED STUDY; DOWN REGULATION; GENE EXPRESSION; GENE OVEREXPRESSION; HELA CELL; HUMAN; HUMAN CELL; PROTEIN EXPRESSION; REPORTER GENE; THYROID PAPILLARY CARCINOMA; UPREGULATION;

BASE SEQUENCE; CARCINOMA, PAPILLARY; CELL CYCLE; DOWN-REGULATION; GENE EXPRESSION REGULATION, NEOPLASTIC; HELA CELLS; HUMANS; INTRACELLULAR SIGNALING PEPTIDES AND PROTEINS; MICRORNAS; THYROID NEOPLASMS; TUMOR CELLS, CULTURED;

EID: 35948975794     PISSN: 13510088     EISSN: None     Source Type: Journal    
DOI: 10.1677/ERC-07-0129     Document Type: Article

References (32)

1. Ambras V 2004 The functions of animal microRNAs. Nature 431 350-355.
2. Baldassarre G, Belletti B, Bruni P, Boccia A, Trapasso F, Pentimalli F, Barone MV, Chiappetta G, Vento MT, Spiezia S et al. 1999 Overexpressed cyclin D3 contributes to retaining the growth inhibitor p27 in the cytoplasm of thyroid tumor cells. Journal of Clinical Investigation 104 865-874.
3. Bartel DP 2004 MicroRNAs: genomics, biogenesis, mechanism, and function. Cell 116 281-297.
4. Calin GA & Croce CM 2006 MicroRNA signatures in human cancers. Nature Reviews. Cancer 6 857-866.
5. Chen J, Jackson PK, Kirschner MW & Dutta A 1995 Separate domains of p21 involved in the inhibition of Cdk kinase and PCNA. Nature 374 386-388.
6. Fero ML, Rivkin M, Tasch M, Porter P, Carow CE, Firpo E, Polyak K, Tsai LH, Broudy V, Perlmutter RM et al. 1996 A syndrome of multiorgan hyperplasia with features of gigantism, tumorigenesis, and female sterility in p27(Kip1)-deficient mice. Cell 85 733-744.
7. Galardi S, Mercatelli N, Giorda E, Massalini S, Frajese GV, Ciafre SA & Farace MG 2007 miR-221 and miR-222 expression affects the proliferation potential of human prostate carcinoma cell lines by targeting p27kip1. Journal of Biological Chemistry 282 23716-23724.
8. Gu Y, Turck CW & Morgan DO 1993 Inhibition of CDK2 activity in vivo by an associated 20K regulatory subunit. Nature 366 707-710.
9. Guan KL, Jenkins CW, Li Y, Nichols MA, Wu X, O'Keefe CL, Matera AG & Xiong Y 1994 Growth suppression by p18, a p16INK4/MTS1- and p14INK4B/MTS2- related CDK6 inhibitor, correlates with wild-type pRb function. Genes and Development 8 2939-2952.
10. Hannon GJ, Casso D & Beach D 1994 KAP: a dual specificity phosphatase that interacts with cyclin-dependent kinases. PNAS 91 1731-1735.
11. He H, Jazdzewski K, Li W, Liyanarachchi S, Nagy R, Volinia S, Calin GA, Liu CG, Franssila K, Suster S et al. 2005 The role of microRNA genes in papillary thyroid carcinoma. PNAS 102 19075-19080.
12. Hirai H, Roussel MF, Kato JY, Ashmun RA & Sherr CJ 1995 Novel INK4 proteins, p19 and p18, are specific inhibitors of the cyclin D-dependent kinases CDK4 and CDK6. Molecular and Cellular Biology 15 2672-2681.
13. John B, Enright AJ, Aravin A, Tuschl T, Sander C & Marks DS 2004 Human MicroRNA targets. PLoS Biology 2 e363.
14. Kaldis P 2007 Another piece of the p27Kip1 puzzle. Cell 128 241-244.
15. Krek A, Grun D, Poy MN, Wolf R, Rosenberg L, Epstein EJ, MacMenamin P, da Piedade I, Gunsalus KC, Stoffel M et al. 2005 Combinatorial microRNA target predictions. Nature Genetics 37 495-500.
16. Lee EJ, Gusev Y, Jiang J, Nuovo GJ, Lerner MR, Frankel WL, Morgan DL, Postier RG, Brackett DJ & Schmittgen TD 2007 Expression profiling identifies microRNA signature in pancreatic cancer. International Journal of Cancer 120 1046-1054.
17. Lewis BP, Shih IH, Jones-Rhoades MW, Bartel DP & Burge CB 2003 Prediction of mammalian microRNA targets. Cell 115 787-798.
18. Lewis BP, Burge CB & Bartel DP 2005 Conserved seed pairing, often flanked by adenosines, indicates that thousands of human genes are microRNA targets. Cell 120 15-20.
19. Liang J, Zubovitz J, Petrocelli T, Kotchetkov R, Connor MK, Han K, Lee JH, Ciarallo S, Catzavelos C, Beniston R et al. 2002 PKB/Akt phosphorylates p27, impairs nuclear import of p27 and opposes p27-mediated G1 arrest. Nature Medicine 8 1153-1160.
20. Megraw M, Sethupathy P, Corda B & Hatzigeorgiou AG 2007 miRGen: a database for the study of animal microRNA genomic organization and function. Nucleic Acids Research 35 D149-D155.
21. Meister G, Landthaler M, Dorsett Y & Tuschl T 2004 Sequence-specific inhibition of microRNA- and siRNA-induced RNA silencing. RNA 10 544-550.
22. Meng F, Henson R, Lang M, Wehbe H, Maheshwari S, Mendell JT, Jiang J, Schmittgen TD & Patel T 2006 Involvement of human micro-RNA in growth and response to chemotherapy in human cholangiocarcinoma cell lines. Gastroenterology 130 2113-2129.
23. Pallante P, Visone R, Ferracin M, Ferraro A, Berlingieri MT, Troncone G, Chiappetta G, Liu CG, Santoro M, Negrini M et al. 2006 MicroRNA deregulation in human thyroid papillary carcinomas. Endocrine-Related Cancer 13 497-508.
24. Polyak K, Lee MH, Erdjument-Bromage H, Koff A, Roberts JM, Tempst P & Massague J 1994 Cloning of p27Kip1, a cyclin-dependent kinase inhibitor and a potential mediator of extracellular antimitogenic signals. Cell 78 59-66.
25. Saltman B, Singh B, Hedvat CV, Wreesmann VB & Ghossein R 2006 Patterns of expression of cell cycle/apoptosis genes along the spectrum of thyroid carcinoma progression. Surgery 140 899-906.
26. Serrano M, Hannon GJ & Beach D 1993 A new regulatory motif in cell-cycle control causing specific inhibition of cyclin D/CDK4. Nature 366 704-707.
27. Shin I, Yakes FM, Rojo F, Shin NY, Bakin AV, Baselga J & Arteaga CL 2002 PKB/Akt mediates cell-cycle progression by phosphorylation of p27(Kip1) at threonine 157 and modulation of its cellular localization. Nature Medicine 8 1145-1152.
28. Slingerland J & Pagano M 2000 Regulation of the cdk inhibitor p27 and its deregulation in cancer. Journal of Cell Physiology 183 10-17.
29. Tallini G, Garcia-Rostan G, Herrero A, Zelterman D, Viale G, Bosari S & Carcangiu ML 1999 Downregulation of p27KIP1 and Ki67/Mib1 labeling index support the classification of thyroid carcinoma into prognostically relevant categories. American Journal of Surgical Pathology 23 678-685.
30. Tanaka J, Ogura T, Sato H & Hatano M 1987 Establishment and biological characterization of an in vitro human cytomegalovirus latency model. Virology 161 62-72.
31. Viglietto G, Motti ML, Bruni P, Melillo RM, D'Alessio A, Califano D, Vinci F, Chiappetta G, Tsichlis P, Bellacosa A et al. 2002 Cytoplasmic relocalization and inhibition of the cyclin-dependent kinase inhibitor p27(Kip1) by PKB/Akt-mediated phosphorylation in breast cancer. Nature Medicine 8 1136-1144.
32. Volinia S, Calin GA, Liu CG, Ambs S, Cimmino A, Petrocca F, Visone R, Iorio M, Roldo C, Ferracin M et al. 2006 A microRNA expression signature of human solid tumors defines cancer gene targets. PNAS 103 2257-2261.